Advertisement

The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis

  • Carla Carnovale
  • Marco Pozzi
  • Alice Dassano
  • Francesca D’Addio
  • Marta Gentili
  • Carlo Magni
  • Emilio Clementi
  • Sonia Radice
  • Paolo Fiorina
Original Article

Abstract

Aims

The effect of HCV eradication following the use of direct-acting antiviral drugs (DAAs) on the glyco-metabolic control is unknown. Through a meta-analysis of available clinical studies, we investigated whether eradication of HCV infection with interferon-free DAAs is associated with improved glyco-metabolic control in diabetic patients.

Methods

We searched the PubMed, MEDLINE and Embase, up to 08th June 2018, for all studies evaluating whether eradication of HCV infection with DAAs is associated with changes in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels from baseline in human subjects, without restrictions for study type and language. Data were independently extracted by two researchers using pre-specified forms. Random effects meta-analyses were conducted on HbA1c and FPG levels before/after HCV eradication.

Results

We found a significant mean reduction in HbA1c levels of − 0.45% (95% CI − 0.60 to − 0.30%; P < 0.001) and in FPG levels of − 22.03 mg/dL (95% CI − 41.61 to − 2.44 mg/dL; P = 0.03), with high heterogeneity between studies (χ2 = 20.4, P < 0.001, I2 = 80% and χ2 = 35.8, P = 0.001, I2 = 94%, respectively). The number of available manuscripts did not allow conducting a meta-regression to elucidate the role of sustained virological response and other confounders in determining the effect of direct-acting antiviral agents on HbA1c reduction.

Conclusions

We found a significant improvement in glyco-metabolic control after HCV eradication (in terms of glycated haemoglobin and fasting plasma glucose levels reduction) following direct-acting antiviral treatment in patients with established diabetes, including a consequent positive impact on anti-diabetic therapies.

Keywords

Glyco-metabolic control HbA1c FPG Direct-acting antiviral agents Hepatitis C 

Abbreviations

HCV

Hepatitis C virus

SVR

Sustained virological response

HbA1c

Haemoglobin A1c, A1C, glycosylated haemoglobin, glycated haemoglobin, glycol-haemoglobin

DAA

Direct-acting antiviral

IFN

Interferon

NOS

Newcastle–Ottawa Scale

CT

Clinical trial

FPG

Fasting plasma glucose

CI

Confidence interval

Notes

Author contributions

CC and MP conceptualized and designed the study, carried out the data extraction and statistical analyses, drafted the manuscript and the summary tables, revised and approved the final manuscript as submitted. AD and FD contributed to literature extraction and manuscript revision and approved the final manuscript as submitted. MG and CM participated in the conceptualization and design of the study, participated in the analysis of the data, revised the article, and approved the final article as submitted. EC and SR participated in the conceptualization and design of the study, participated in the analysis and interpretation of the data, revised the article, and approved the final article as submitted. PF contributed to concept and design of the study, participated in the analysis and interpretation of the data, coordinated and supervised data collection, critically reviewed the manuscript and approved the final manuscript as submitted. PF is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

The financial support by the Agenzia Italiana del Farmaco (AIFA), by the Centre of Pharmacovigilance of Regione Lombardia (MEAP project, Monitoraggio degli Eventi Avversi nelle Popolazioni a Rischio, to EC), by the Italian Ministry of Health (RC 2017 to EC) and the Italian Ministry of Health (Ricerca Corrente 2018, to MP) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent

For this type of study formal consent is not required.

Supplementary material

592_2018_1257_MOESM1_ESM.docx (323 kb)
Supplementary material 1 (DOCX 322 KB)

References

  1. 1.
    World Health Organization. Hepatitis C. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 2 Jun 2018
  2. 2.
    Lecube A, Hernández C, Genescà J, Simó R (2006) Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 29:1140–1149CrossRefGoogle Scholar
  3. 3.
    Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L et al (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333CrossRefGoogle Scholar
  4. 4.
    Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A et al (2014) Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 5:586–600CrossRefGoogle Scholar
  5. 5.
    Naing C, Mak JW, Ahmed SI, Maung M (2012) Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 18:1642–1651CrossRefGoogle Scholar
  6. 6.
    Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43:1295–1302CrossRefGoogle Scholar
  7. 7.
    Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856–1862CrossRefGoogle Scholar
  8. 8.
    Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T et al (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499–1508CrossRefGoogle Scholar
  9. 9.
    Parvaiz F, Manzoor S, Iqbal J, Sarkar-Dutta M, Imran M, Waris G (2015) Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J Gastroenterol 21:12361–12369CrossRefGoogle Scholar
  10. 10.
    Shi H, Tzameli I, Bjørbaek C, Flier JS (2004) Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 279:34733–34740CrossRefGoogle Scholar
  11. 11.
    Basaranoglu M, Basaranoglu G (2011) Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 17:4055–4062CrossRefGoogle Scholar
  12. 12.
    Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I (2011) Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J 18:474CrossRefGoogle Scholar
  13. 13.
    Lecube A, Hernández C, Genescà J, Simó R (2006) Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 29:1096–1101CrossRefGoogle Scholar
  14. 14.
    Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM et al (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636–641CrossRefGoogle Scholar
  15. 15.
    Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG et al (2008) Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48:28–34CrossRefGoogle Scholar
  16. 16.
    Simó R, Lecube A, Genescà J, Esteban JI, Hernández C (2006) Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29:2462–2466CrossRefGoogle Scholar
  17. 17.
    Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y (2010) Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 8:458–462CrossRefGoogle Scholar
  18. 18.
    Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD (2017) Improvement in glycemic control of type 2 diabetes after successful treatmen of hepatitis C virus. Diabetes Care 40:1173–1180CrossRefGoogle Scholar
  19. 19.
    Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E et al (2018) Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol 90:320–327CrossRefGoogle Scholar
  20. 20.
    Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R et al (2017) No improvement in hemoglobin A1c following hepatitis C viral clearance in patients with and without HIV. J Infect Dis 217:47–50CrossRefGoogle Scholar
  21. 21.
    Carvalho JR, Velosa J, Serejo F (2018) Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication-comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol 20:1–7Google Scholar
  22. 22.
    Prospero international prospective register of systematic reviews. Available from: https://www.crd.york.ac.uk/PROSPERO/. Accessed 2 Jun 2018
  23. 23.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269CrossRefGoogle Scholar
  24. 24.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefGoogle Scholar
  25. 25.
    Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Bräu N (2006) Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C. J Viral Hepat 13:613–617CrossRefGoogle Scholar
  26. 26.
    Unnikrishnan R, Anjana RM, Mohan V (2012) Drugs affecting HbA1c levels. Indian J Endocrinol Metab 16:528–531CrossRefGoogle Scholar
  27. 27.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 Jun 2018
  28. 28.
    Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384CrossRefGoogle Scholar
  29. 29.
    AASLD-IDSA Recommendations for testing, management, and treating hepatitis C. Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. Available from https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018a.pdf. Accessed 2 Jun 2018
  30. 30.
    Burgess SV, Hussaini T, Yoshida EM (2016) Concordance of sustained virological response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review. Ann Hepatol 15:154–159PubMedGoogle Scholar
  31. 31.
    Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L et al (2010) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virological response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51:1122–1126CrossRefGoogle Scholar
  32. 32.
    European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66:153–194CrossRefGoogle Scholar
  33. 33.
    Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S et al (2017) Improvement of glycemic state among responders to sofosbuvir-based treatment regimens: single center experience. J Med Virol 89:2181–2187CrossRefGoogle Scholar
  34. 34.
    Ikeda A, Ikeda K, Takai A, Takahashi K, Ueda Y, Marusawa H et al (2017) Hepatitis C treatment with sofosbuvir and ledipasvir accompanied by immediate improvement in hemoglobin A1c. Digestion 96:228–230CrossRefGoogle Scholar
  35. 35.
    Beig J, Orr D, Harrison B, Gane E (2018) HCV eradication with new IFN free treatment improves metabolic profile in HCV-related liver transplant recipients. Liver Transpl.  https://doi.org/10.1002/lt.25060 CrossRefPubMedGoogle Scholar
  36. 36.
    Dawood AA, Nooh MZ, Elgamal AA (2017) Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J 41:316–321CrossRefGoogle Scholar
  37. 37.
    Fabrizio C, Procopio A, Scudeller L, Dell’Acqua R, Bruno G, Milano E (2017) HCV and diabetes: towards a ‘sustained’ glycaemic improvement after treatment with DAAs? Clin Microbiol Infect 23:342–343CrossRefGoogle Scholar
  38. 38.
    Pashun RA, Shen NT, Jesudian A (2016) Markedly improved glycemic control in poorly controlled type 2 diabetes following direct acting antiviral treatment of genotype 1 hepatitis C. Case Rep Hepatol. 2016:7807921Google Scholar
  39. 39.
    Stine JG. Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL (2017) Effect of treatment with direct acting antiviral on glycemic control in patients with diabetes mellitus and chronic hepatitis C. Ann Hepatol 16:215–220PubMedGoogle Scholar
  40. 40.
    Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF et al (2017) The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. J Med Sci 33:567–571Google Scholar
  41. 41.
    Lenters-Westra E, Schindhelm RK, Bilo HJ, Groenier KH, Slingerland RJ (2014) Differences in interpretation of haemoglobin A1c values among diabetes care professionals. Neth J Med 72:462–466PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Carla Carnovale
    • 1
  • Marco Pozzi
    • 2
  • Alice Dassano
    • 3
  • Francesca D’Addio
    • 3
  • Marta Gentili
    • 1
  • Carlo Magni
    • 4
  • Emilio Clementi
    • 1
    • 2
  • Sonia Radice
    • 1
  • Paolo Fiorina
    • 3
    • 5
    • 6
  1. 1.Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University HospitalUniversità di MilanoMilanItaly
  2. 2.Scientific Institute IRCCS Eugenio MedeaBosisio PariniItaly
  3. 3.International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. SaccoUniversità di MilanoMilanItaly
  4. 4.1st Division of Infectious DiseasesASST Fatebenefratelli-SaccoMilanItaly
  5. 5.Nephrology Division, Boston Children’s HospitalHarvard Medical SchoolBostonUSA
  6. 6.Division of EndocrinologyASST Fatebenefratelli-SaccoMilanItaly

Personalised recommendations